Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSC-exosome nebulization product
- Development stage
- Preclinical
- Lead developer
- Guangzhou Double Bioproducts
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Inhalation
01
Overview
The MSC-exosome nebulization product is an investigational cell-free biologic developed by Guangzhou Double Bioproducts (Guangzhou Doublle Bioproducts). The therapy consists of mesenchymal stem cell (MSC)-derived exosomes, which are nanoscale extracellular vesicles secreted by MSCs. Formulated for delivery via inhalation or nebulization, the product is designed to deliver bioactive cargo—including proteins, miRNA, and mRNA—directly to the bronchioles and alveoli. This mechanism is intended to leverage the paracrine and immunomodulatory properties of MSC-derived exosomes to promote the repair of bronchial and pulmonary tissues damaged by infection or other respiratory injuries. As a cell-free alternative to whole-cell MSC therapies, it aims to reduce inflammation and support tissue regeneration in conditions such as bronchial and lung infectious injury.
- Other names
- MSC-Exo雾化产品MSC-Exo Nebulization Product
Beyond the preview
Go deeper on MSC-exosome nebulization product.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MSC-exosome nebulization product.